An old malaria drug gets a new formulation. But how good is it – and will it drive resistance?

In this podcast, we ask:

• What are the limitations of current malaria vaccines?
• What is the concept of long-acting injectable (LAI) drugs?
• What are the clinical and chemical properties of atovaquone that make it suitable for this purpose?

With Theresa Shapiro, Professor, Johns Hopkins School of Medicine and Division Director, Division of Clinical Pharmacology.

The Johns Hopkins Malaria Minute is produced by the Johns Hopkins Malaria Research Institute to highlight impactful malaria research and to share it with the global community.